Cargando…

Outcome of ovarian cancer after breast cancer in BRCA1 and BRCA2 mutation carriers

BACKGROUND: It is unknown whether a history of breast cancer (BC) affects the outcome of BRCA1/2-associated epithelial ovarian cancer (EOC). This was investigated in the current analysis. METHODS: We included 386 BRCA1/2-associated EOC patients diagnosed between 1980 and 2015. Progression-free survi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zaaijer, Leendert H, van Doorn, Helena C, Mourits, Marian J E, van Beurden, Marc, de Hullu, Joanne A, Adank, Muriel A, van Lonkhuijzen, Luc R C W, Vasen, Hans F A, Slangen, Brigitte F M, Gaarenstroom, Katja N, Zweemer, Ronald P, Vencken, Peggy M L H, Seynaeve, Caroline, Kriege, Mieke
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2016
Materias:	Short Communication
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5104898/ https://www.ncbi.nlm.nih.gov/pubmed/27755534 http://dx.doi.org/10.1038/bjc.2016.333

Ejemplares similares

Cancer worry among BRCA1/2 pathogenic variant carriers choosing surgery to prevent tubal/ovarian cancer: course over time and associated factors
por: van Bommel, Majke H. D., et al.
Publicado: (2022)

High-Grade Serous Carcinoma at Risk-Reducing Salpingo-Oophorectomy in Asymptomatic Carriers of BRCA1/2 Pathogenic Variants: Prevalence and Clinical Factors
por: Stroot, Iris A.S., et al.
Publicado: (2023)

Early salpingectomy (TUbectomy) with delayed oophorectomy to improve quality of life as alternative for risk-reducing salpingo-oophorectomy in BRCA1/2 mutation carriers (TUBA study): a prospective non-randomised multicentre study
por: Harmsen, Marline G., et al.
Publicado: (2015)

No efficacy of annual gynaecological screening in BRCA1/2 mutation carriers; an observational follow-up study
por: Hermsen, B B J, et al.
Publicado: (2007)

Endometrial Cancer Risk in Women With Germline BRCA1 or BRCA2 Mutations: Multicenter Cohort Study
por: de Jonge, Marthe M, et al.
Publicado: (2021)

A patient decision aid for risk‐reducing surgery in premenopausal BRCA1/2 mutation carriers: Development process and pilot testing
por: Harmsen, Marline G., et al.
Publicado: (2017)

Toxicity of (neo)adjuvant chemotherapy for BRCA1- and BRCA2-associated breast cancer
por: Drooger, Jan C., et al.
Publicado: (2016)

Clinical outcome of prophylactic oophorectomy in BRCA1/BRCA2 mutation carriers and events during follow-up
por: Olivier, R I, et al.
Publicado: (2004)

Effects of chemotherapy on contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers: A nationwide cohort study
por: Akdeniz, Delal, et al.
Publicado: (2021)

Screening for BRCA2 mutations in 81 Dutch breast–ovarian cancer families
por: Peelen, T, et al.
Publicado: (2000)

Oral Contraceptive Use in BRCA1 and BRCA2 Mutation Carriers: Absolute Cancer Risks and Benefits
por: Schrijver, Lieske H, et al.
Publicado: (2022)

Progression-free survival and overall survival after BRCA1/2-associated epithelial ovarian cancer: A matched cohort study
por: Heemskerk-Gerritsen, Bernadette A. M., et al.
Publicado: (2022)

The Effect of Risk-Reducing Salpingo-Oophorectomy on Breast Cancer Incidence and Histopathological Features in Women with a BRCA1 or BRCA2 Germline Pathogenic Variant
por: Stuursma, Annechien, et al.
Publicado: (2023)

The Influence of Number and Timing of Pregnancies on Breast Cancer Risk for Women With BRCA1 or BRCA2 Mutations
por: Terry, Mary Beth, et al.
Publicado: (2019)

Characteristics of small breast and/or ovarian cancer families with germline mutations in BRCA1 and BRCA2
por: Ligtenberg, M J L, et al.
Publicado: (1999)

Risks of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers
por: Ahmed, M, et al.
Publicado: (2010)

Genome-wide scanning for linkage in 56 Dutch breast cancer families selected for a minimal probability of being due to BRCA1 or BRCA2
por: Oldenburg, RA, et al.
Publicado: (2005)

The incidence of pancreatic cancer in BRCA1 and BRCA2 mutation carriers
por: Iqbal, J, et al.
Publicado: (2012)

BRCA promoter methylation in sporadic versus BRCA germline mutation-related breast cancers
por: Vos, Shoko, et al.
Publicado: (2017)

The pathology of familial breast cancer: The pre-BRCA1/BRCA2 era - historical perspectives
por: van de Vijver, Marc J
Publicado: (1999)

Contraceptives and cancer risks in BRCA1/2 pathogenic variant carriers: a systematic review and meta-analysis
por: van Bommel, Majke H D, et al.
Publicado: (2022)

Survival after bilateral risk-reducing mastectomy in healthy BRCA1 and BRCA2 mutation carriers
por: Heemskerk-Gerritsen, Bernadette A. M., et al.
Publicado: (2019)

Phase 1 trial of olaparib and oral cyclophosphamide in BRCA breast cancer, recurrent BRCA ovarian cancer, non-BRCA triple-negative breast cancer, and non-BRCA ovarian cancer
por: Lee, Chee Khoon, et al.
Publicado: (2019)

Cancer Risks Associated With BRCA1 and BRCA2 Pathogenic Variants
por: Li, Shuai, et al.
Publicado: (2022)

Gastric Cancer Risk and Pathogenesis in BRCA1 and BRCA2 Carriers
por: Buckley, Kole H., et al.
Publicado: (2022)

Clinical impact of detection of loss of heterozygosity of BRCA1 and BRCA2 markers in sporadic breast cancer.
por: Beckmann, M. W., et al.
Publicado: (1996)

Analysis of BRCA1- and BRCA2-Related Pancreatic Cancer and Survival
por: Boursi, Ben, et al.
Publicado: (2023)

Plasma osteoprotegerin and breast cancer risk in BRCA1 and BRCA2 mutation carriers
por: Odén, Lovisa, et al.
Publicado: (2016)

Breast cancer prevention in women with a BRCA1 or BRCA2 mutation
por: Metcalfe, Kelly A, et al.
Publicado: (2007)

Looking for BRCA1 and BRCA2 mutations in Asian women with breast cancer
por: Narod, Steven A.
Publicado: (2023)

Autoimmune response to PARP and BRCA1/BRCA2 in cancer
por: Zhu, Qing, et al.
Publicado: (2015)

Risk reduction of contralateral breast cancer and survival after contralateral prophylactic mastectomy in BRCA1 or BRCA2 mutation carriers
por: van Sprundel, T C, et al.
Publicado: (2005)

The role of BRCA1 and BRCA2 mutations in prostate, pancreatic and stomach cancers
por: Cavanagh, Helen, et al.
Publicado: (2015)

An international initiative to identify genetic modifiers of cancer risk in BRCA1 and BRCA2 mutation carriers: the Consortium of Investigators of Modifiers of BRCA1 and BRCA2 (CIMBA)
por: Chenevix-Trench, Georgia, et al.
Publicado: (2007)

Survival of BRCA1/BRCA2-associated pT1 breast cancer patients, a cohort study
por: van Barele, Mark, et al.
Publicado: (2022)

Adjuvant radiotherapy for primary breast cancer in BRCA1 and BRCA2 mutation carriers and risk of contralateral breast cancer with special attention to patients irradiated at younger age
por: Drooger, Jan C., et al.
Publicado: (2015)

Sequence Variants of BRCA1 and BRCA2 Genes in Four Iranian Families with Breast and Ovarian Cancer
por: Keshavarzi, F, et al.
Publicado: (2011)

Predictors of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers
por: Metcalfe, K, et al.
Publicado: (2011)

Novel BRCA1 and BRCA2 Tumor Test as Basis for Treatment Decisions and Referral for Genetic Counselling of Patients with Ovarian Carcinomas
por: Weren, Robbert D.A., et al.
Publicado: (2016)

Associations of height, body mass index, and weight gain with breast cancer risk in carriers of a pathogenic variant in BRCA1 or BRCA2: the BRCA1 and BRCA2 Cohort Consortium
por: Kast, Karin, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_e3h5rsht7aq1t0uave6ajhhc0b